Paul Glue: Ibogaine & Opioid Withdrawal - Does it Work and Is it Safe?

Ibogaine and its metabolite noribogaine act as potential treatments for opioid withdrawal whose clinical application remains hindered by critical safety and pharmacological knowledge gaps. Research studies conducted in New Zealand have focused on establishing safe dosing ranges and characterizing their metabolic profile, specifically highlighting the role of the CYP2D6 enzyme in noribogaine processing. Results underscore that CYP2D6 inhibition causes significant exposure increases, leading to potential cardiovascular risks such as QTc interval prolongation, which necessitates rigorous heart monitoring during clinical use. Further research is required to resolve how these substances interact with opioid withdrawal processes beyond preliminary early phase findings.